Christopher Peetz News Today

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note issued on Tuesday, January 9th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of $3.37 for the year, […]

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “market outperform” rating reiterated by research analysts at JMP Securities in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $64.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 142.15% from […]

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 5,209 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $28.03, for a total value of $146,008.27. Following the completion of the sale, the chief executive officer now directly […]

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript November 5, 2023 Operator: Good afternoon. I would like to welcome you all to the Mirum Pharmaceuticals Conference Call. My name is Brika and I’ll be the event specialist running today’s call with you. [Operator Instructions]. I would now like to pass the call over to […]

HC Wainwright reaffirmed their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a report released on Friday morning, Benzinga reports. They currently have a $63.00 price objective on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2024 earnings at $0.23 EPS, Q3 2024 earnings at $0.38 EPS, Q4 […]

Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its price target decreased by Raymond James from $82.00 to $79.00 in a research report released on Friday morning, Benzinga reports. Raymond James currently has a strong-buy rating on the stock. Separately, HC Wainwright upped their target price on Mirum Pharmaceuticals from $61.00 to $63.00 and gave the […]

Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its target price cut by Raymond James from $82.00 to $79.00 in a research report report published on Friday morning, Benzinga reports. They currently have a strong-buy rating on the stock. Separately, HC Wainwright upped their price objective on shares of Mirum Pharmaceuticals from $61.00 to $63.00 and […]

Key Insights Institutions' substantial holdings in Mirum Pharmaceuticals implies that they have significant influence...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) gapped down prior to trading on Wednesday . The stock had previously closed at $30.09, but opened at $28.50. Mirum Pharmaceuticals shares last traded at $28.65, with a volume of 109,835 shares traded. Analyst Upgrades and Downgrades MIRM has been the topic of a number of research reports. […]

NEA Management Company LLC reduced its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) by 0.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,186,243 shares of the company’s stock after selling 1,558 shares during the quarter. Mirum Pharmaceuticals […]